X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Robert Zirkelbach

Robert Zirkelbach Robert Zirkelbach is Executive Vice President of Public Affairs at PhRMA. He joins PhRMA in 2014 after working for seven years representing the health insurance industry. He likes Saturday afternoon BBQs on his deck, traveling, trying new restaurants, and attempting to play golf. He’s an avid, somewhat obsessive, Iowa Hawkeye fan and is lucky to have a wife that loves watching college football on Saturday afternoons.

Recent Posts

CSRxP proposals would undermine competitive market, harm patients and innovation

By Robert Zirkelbach  |    April 25, 2016
These so-called market-based proposals are nothing more than a litany of new government regulations and mandates that would undermine the competitive market and empower government bureaucrats and...   Read More

ICYMI: Policy solutions for delivering innovative treatments to patients

By Robert Zirkelbach  |    March 11, 2016
Yesterday, at the PhRMA 2016 Annual Meeting, PhRMA president and CEO Steve Ubl laid out his vision for the organization and released policy solutions for delivering innovative treatments to...   Read More

PhRMA Statement on Medicare Drug Spending Dashboard

By Robert Zirkelbach  |    December 21, 2015
The prescription drug spending data released by the Centers for Medicare & Medicaid Services (CMS) today provide a misleading and incomplete picture of actual Medicare spending on prescription...   Read More

What you need to know about access to innovative medicines in the U.S.

By Robert Zirkelbach  |    December 1, 2015
Today the Wall Street Journal published another story on prescription drug spending that cherry-picks Medicare Part B data in an effort to compare medicine prices in the U.S. to other countries....   Read More

6 things to know before the HHS forum

By Robert Zirkelbach  |    November 19, 2015
Tomorrow, the Department of Health and Human Services (HHS) will host a forum on pharmaceutical innovation, access, affordability and better health. We welcome the opportunity to discuss how we...   Read More

What makes Valeant different than innovative biopharmaceutical companies?

By Robert Zirkelbach  |    October 22, 2015
Much like Turing, Valeant Pharmaceutical’s strategy is more reflective of a hedge fund than an innovative biopharmaceutical company. Valeant’s CEO has stated that the company’s “strategy is quite...   Read More

New poll finds majority of voters oppose government price-setting for prescription drugs

By Robert Zirkelbach  |    September 23, 2015
Majority of voters (51 percent compared to 36 percent) oppose allowing the federal government to set the price of prescription medicines, a poll released today found. The Morning Consult poll of...   Read More

3 Points You Need to Know about the Federal Government’s Health Spending Projections

By Robert Zirkelbach  |    July 28, 2015
New National Health Expenditure (NHE) projections released today by the Centers for Medicare & Medicaid Services (CMS) call into question claims that have been made in recent months about the...   Read More

Focusing on Only 1% of Spending Will Not Solve Nation’s Health Care Challenges

By Robert Zirkelbach  |    July 23, 2015
Commentary published today in Mayo Clinic Proceedings highlights a critical challenge facing cancer patients: the ability to access the medicines they need. But rather than address this issue...   Read More

Are new hep C treatments cost effective? Doctors say answer is “a resounding yes”

By Robert Zirkelbach  |    July 14, 2015
In case you missed it, a recent Bloomberg story features a new report from an influential panel of doctors and medical experts which finds that new treatments for hepatitis C are “cost effective.”...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates